PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 25831967-0 2015 Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). Vortioxetine 51-63 5-hydroxytryptamine receptor 1A Homo sapiens 202-207 25831967-0 2015 Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). Vortioxetine 51-63 5-hydroxytryptamine receptor 1B Homo sapiens 209-214 25831967-0 2015 Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). Vortioxetine 51-63 5-hydroxytryptamine receptor 1D Homo sapiens 216-221 34964415-5 2022 EXPERT OPINION: Vortioxetine is the first antidepressant that has shown improvements both in depression and cognitive symptoms, due to the unique multimodal mechanism of action that combine the 5-HT reuptake inhibition with modulations of other key pre- and post-synaptic 5-HT receptors (agonism of 5-HT1A receptor, partial agonism of 5-HT1B receptor, and antagonism of 5-HT3, 5-HT1D and 5-HT7 receptors). Vortioxetine 16-28 5-hydroxytryptamine receptor 1A Homo sapiens 299-314 34964415-5 2022 EXPERT OPINION: Vortioxetine is the first antidepressant that has shown improvements both in depression and cognitive symptoms, due to the unique multimodal mechanism of action that combine the 5-HT reuptake inhibition with modulations of other key pre- and post-synaptic 5-HT receptors (agonism of 5-HT1A receptor, partial agonism of 5-HT1B receptor, and antagonism of 5-HT3, 5-HT1D and 5-HT7 receptors). Vortioxetine 16-28 5-hydroxytryptamine receptor 1D Homo sapiens 377-383 34576176-0 2021 Distinct Effects of Escitalopram and Vortioxetine on Astroglial L-Glutamate Release Associated with Connexin43. Vortioxetine 37-49 gap junction protein, alpha 1 Rattus norvegicus 100-110 34121163-1 2021 INTRODUCTION: Vortioxetine is an antidepressant primarily metabolized by the polymorphic enzyme cytochrome P450 (CYP) 2D6. Vortioxetine 14-26 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 96-121 34121163-2 2021 A population pharmacokinetic (popPK) model of vortioxetine and its CYP2D6-dependent metabolite was recently published. Vortioxetine 46-58 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 67-73 34121163-13 2021 The tendency of the popPK model to overpredict vortioxetine concentrations measured in TDM may be attributed to several factors, including poor treatment compliance for some patients and, to a lesser extent, lack of information on patient characteristics and misspecified CYP2D6 alleles. Vortioxetine 47-59 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 272-278 34894110-8 2022 Also, there was a significant decrease in the right central delta band and an increase in the right central beta 2 band following vortioxetine treatment. Vortioxetine 130-142 ATPase H+ transporting V0 subunit a2 Homo sapiens 108-114 34358549-0 2021 Vortioxetine mitigates neuronal damage by restricting PERK/eIF2alpha/ATF4/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion. Vortioxetine 0-12 eukaryotic translation initiation factor 2A Rattus norvegicus 59-68 34358549-0 2021 Vortioxetine mitigates neuronal damage by restricting PERK/eIF2alpha/ATF4/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion. Vortioxetine 0-12 activating transcription factor 4 Rattus norvegicus 69-73 34358549-0 2021 Vortioxetine mitigates neuronal damage by restricting PERK/eIF2alpha/ATF4/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion. Vortioxetine 0-12 DNA-damage inducible transcript 3 Rattus norvegicus 74-78 34358549-2 2021 Vortioxetine (VTX) is a multimodal antidepressant agent that balances 5-HT receptors and represses the serotonin transporter. Vortioxetine 0-12 solute carrier family 6 member 4 Rattus norvegicus 103-124 34358549-2 2021 Vortioxetine (VTX) is a multimodal antidepressant agent that balances 5-HT receptors and represses the serotonin transporter. Vortioxetine 14-17 solute carrier family 6 member 4 Rattus norvegicus 103-124 34358549-10 2021 Moreover, ELISA revealed an increase in the levels of ATF4, IRE1, Apaf-1, and HIF-1alpha, while VTX administration ameliorated most of these perturbations induced after MCAO injury. Vortioxetine 96-99 activating transcription factor 4 Rattus norvegicus 54-58 34358549-10 2021 Moreover, ELISA revealed an increase in the levels of ATF4, IRE1, Apaf-1, and HIF-1alpha, while VTX administration ameliorated most of these perturbations induced after MCAO injury. Vortioxetine 96-99 apoptotic peptidase activating factor 1 Rattus norvegicus 66-72 34358549-10 2021 Moreover, ELISA revealed an increase in the levels of ATF4, IRE1, Apaf-1, and HIF-1alpha, while VTX administration ameliorated most of these perturbations induced after MCAO injury. Vortioxetine 96-99 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 78-88 34576176-5 2021 Subchronic (for seven days) administrations of vortioxetine and the 5-HT7R inverse agonist (SB269970) suppressed both basal L-glutamate release and L-glutamate release through activated hemichannels, whereas 5-HT1AR agonist (BP554) inhibited L-glutamate release through activated hemichannels, but did not affect basal L-glutamate release. Vortioxetine 47-59 ferredoxin reductase Rattus norvegicus 213-215 34576176-7 2021 Subchronic administration of vortioxetine, BP554 and SB269970 downregulated 5-HT1AR, 5-HT7R and phosphorylated ERK in the plasma membrane fraction, but escitalopram and WAY100635 did not affect them. Vortioxetine 29-41 Eph receptor B1 Rattus norvegicus 111-114 34576176-9 2021 Subchronic vortioxetine administration increased Cx43 expression in the cytosol and decreased it in the plasma membrane. Vortioxetine 11-23 gap junction protein, alpha 1 Rattus norvegicus 49-53 34576176-10 2021 WAY100635 prevented an increased Cx43 expression in the cytosol induced by vortioxetine without affecting the reduced Cx43 expression in the plasma membrane. Vortioxetine 75-87 gap junction protein, alpha 1 Rattus norvegicus 33-37 34576176-12 2021 These results also suggest that the subchronic administration of therapeutic-relevant concentrations of vortioxetine inhibits both astroglial L-glutamate and Cx43 expression in the plasma membrane via 5-HT7R downregulation but enhances Cx43 synthesis in the cytosol via 5-HT1AR downregulation. Vortioxetine 104-116 gap junction protein, alpha 1 Rattus norvegicus 158-162 34576176-12 2021 These results also suggest that the subchronic administration of therapeutic-relevant concentrations of vortioxetine inhibits both astroglial L-glutamate and Cx43 expression in the plasma membrane via 5-HT7R downregulation but enhances Cx43 synthesis in the cytosol via 5-HT1AR downregulation. Vortioxetine 104-116 gap junction protein, alpha 1 Rattus norvegicus 236-240 34576176-13 2021 This combination of the downregulation of 5-HT1AR, 5-HT7R and Cx43 in the astroglial plasma membrane induced by subchronic vortioxetine administration suggest that astrocytes is possibly involved in the pathophysiology of depression. Vortioxetine 123-135 gap junction protein, alpha 1 Rattus norvegicus 62-66 34211395-0 2021 Hippocampal PPARalpha Plays a Role in the Pharmacological Mechanism of Vortioxetine, a Multimodal-Acting Antidepressant. Vortioxetine 71-83 peroxisome proliferator activated receptor alpha Mus musculus 12-21 34211395-1 2021 As a well-known multimodal-acting antidepressant, vortioxetine is thought to aim at several serotonin (5-HT) receptors and the 5-HT transporter. Vortioxetine 50-62 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 127-143 34211395-5 2021 Here we speculate that hippocampal PPARalpha may participate in the antidepressant mechanism of vortioxetine. Vortioxetine 96-108 peroxisome proliferator activated receptor alpha Mus musculus 35-44 34211395-7 2021 It was found that vortioxetine administration significantly reversed the inhibitory actions of both CUMS and CSDS on the hippocampal PPARalpha expression. Vortioxetine 18-30 peroxisome proliferator activated receptor alpha Mus musculus 133-142 34211395-8 2021 Pharmacological blockade of PPARalpha notably prevented the antidepressant actions of vortioxetine in the CUMS and CSDS models. Vortioxetine 86-98 peroxisome proliferator activated receptor alpha Mus musculus 28-37 34211395-9 2021 Moreover, genetic knockdown of PPARalpha in the hippocampus also significantly blocked the protecting effects of vortioxetine against both CUMS and CSDS. Vortioxetine 113-125 peroxisome proliferator activated receptor alpha Mus musculus 31-40 34211395-10 2021 Therefore, the antidepressant effects of vortioxetine in mice require hippocampal PPARalpha. Vortioxetine 41-53 peroxisome proliferator activated receptor alpha Mus musculus 82-91 35092748-0 2022 Vortioxetine ameliorates motor and cognitive impairments in the rotenone-induced Parkinson"s disease via targeting TLR-2 mediated neuroinflammation. Vortioxetine 0-12 toll-like receptor 2 Rattus norvegicus 115-120 35508799-4 2022 RESULTS: Based on the docking scores predicted by ADV and AD, most vortioxetine derivatives showed better binding efficiency towards Mpro of SARS-CoV-2 in comparison with remdesivir (an EUA approved drug against SARS-CoV-2 Mpro) and vortioxetine. Vortioxetine 67-79 NEWENTRY Severe acute respiratory syndrome-related coronavirus 133-137 35508799-4 2022 RESULTS: Based on the docking scores predicted by ADV and AD, most vortioxetine derivatives showed better binding efficiency towards Mpro of SARS-CoV-2 in comparison with remdesivir (an EUA approved drug against SARS-CoV-2 Mpro) and vortioxetine. Vortioxetine 67-79 NEWENTRY Severe acute respiratory syndrome-related coronavirus 223-227 34071269-0 2021 5-HT1A Serotonergic, alpha-Adrenergic and Opioidergic Receptors Mediate the Analgesic Efficacy of Vortioxetine in Mice. Vortioxetine 98-110 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 0-6 34071269-10 2021 Obtained findings indicated that vortioxetine-induced analgesia is mediated by 5-HT1A serotonergic, alpha-adrenergic and opioidergic receptors, and contributions of central serotonergic and catecholaminergic neurotransmissions are critical for this effect. Vortioxetine 33-45 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 79-85 35298873-4 2022 The most interesting structural match involved the drug vortioxetine which was then experimentally shown by NMR spectroscopy to bind directly to human ACE2. Vortioxetine 56-68 angiotensin converting enzyme 2 Homo sapiens 151-155 35092748-9 2022 Interestingly, vortioxetine was thought to trigger a sort of dysfunction in basal ganglia as evidenced by increased Toll-like receptor-2 (TLR-2) and decreased TH immunoreactivity only in substantia nigra tissue of PD rats compared to the control group. Vortioxetine 15-27 toll-like receptor 2 Rattus norvegicus 116-136 35092748-9 2022 Interestingly, vortioxetine was thought to trigger a sort of dysfunction in basal ganglia as evidenced by increased Toll-like receptor-2 (TLR-2) and decreased TH immunoreactivity only in substantia nigra tissue of PD rats compared to the control group. Vortioxetine 15-27 toll-like receptor 2 Rattus norvegicus 138-143 33560444-7 2021 A moderate positive correlation between pretreatment plasma BDNF levels and improvement in cognitive performance was only detected in patients treated with vortioxetine (delta F-A-S test: p=0.011; r=0.325, delta Digit Span test-forward span: p=0.010, r=0.326). Vortioxetine 156-168 brain derived neurotrophic factor Homo sapiens 60-64 35146812-0 2022 In vivo electrophysiological study of the targeting of 5-HT3 receptor-expressing cortical interneurons by the multimodal antidepressant, vortioxetine. Vortioxetine 137-149 5-hydroxytryptamine receptor 3A Rattus norvegicus 55-69 35146812-1 2022 The antidepressant vortioxetine has high affinity for the ionotropic 5-HT3 receptor (5-HT3 R) as well as other targets including the 5-HT transporter. Vortioxetine 19-31 5-hydroxytryptamine receptor 3A Rattus norvegicus 69-83 35146812-1 2022 The antidepressant vortioxetine has high affinity for the ionotropic 5-HT3 receptor (5-HT3 R) as well as other targets including the 5-HT transporter. Vortioxetine 19-31 5-hydroxytryptamine receptor 3A Rattus norvegicus 85-92 35146812-1 2022 The antidepressant vortioxetine has high affinity for the ionotropic 5-HT3 receptor (5-HT3 R) as well as other targets including the 5-HT transporter. Vortioxetine 19-31 solute carrier family 6 member 4 Rattus norvegicus 133-149 35146812-3 2022 Thus, vortioxetine purportedly inhibits cortical 5-HT3 R-expressing interneurons (5-HT3 R-INs) to disinhibit excitatory pyramidal neurons. Vortioxetine 6-18 5-hydroxytryptamine receptor 3A Rattus norvegicus 49-56 35146812-3 2022 Thus, vortioxetine purportedly inhibits cortical 5-HT3 R-expressing interneurons (5-HT3 R-INs) to disinhibit excitatory pyramidal neurons. Vortioxetine 6-18 5-hydroxytryptamine receptor 3A Rattus norvegicus 82-89 35146812-4 2022 The current study determined for the first time, the effect of vortioxetine on the in vivo firing of putative 5-HT3 R-INs whilst simultaneously recording pyramidal neuron activity using cortical slow-wave oscillations as a readout. Vortioxetine 63-75 5-hydroxytryptamine receptor 3A Rattus norvegicus 110-117 35146812-8 2022 Vortioxetine inhibited the short-latency DRN-evoked excitation of 5-HT3 R-INs and simultaneously decreased cortical slow wave oscillations, indicative of pyramidal neuron activation. Vortioxetine 0-12 5-hydroxytryptamine receptor 3A Rattus norvegicus 66-73 35146812-12 2022 Overall, the current findings suggest that vortioxetine simultaneously inhibits (DRN-evoked) 5-HT3 R-INs and excites pyramidal neurons, thereby changing the excitatory:inhibitory balance in cortex. Vortioxetine 43-55 5-hydroxytryptamine receptor 3A Rattus norvegicus 93-100 33560444-0 2021 Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram. Vortioxetine 108-120 brain derived neurotrophic factor Homo sapiens 31-35 33560444-8 2021 CONCLUSIONS: These results suggest that higher baseline plasma BDNF levels might be associated with improvements in verbal fluency and working memory in vortioxetine, but not escitalopram treated patients. Vortioxetine 153-165 brain derived neurotrophic factor Homo sapiens 63-67 33587394-2 2021 Vortioxetine, a recently developed antidepressant, acts as a serotonin modulator through inhibition of the serotonin transporter and actions at multiple types of serotonin receptors. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 107-128 33485943-7 2021 Moreover, systemic 21-day treatment with vortioxetine, a novel multimodal antidepressant, successfully reversed depression-like behaviors and normalized some molecular changes, including that of the norepinephrine transporter in the medial prefrontal cortex, vesicular monoamine transporter 2 in nucleus accumbens core, and serotonin transporter in amygdala. Vortioxetine 41-53 solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 Mus musculus 199-225 33485943-7 2021 Moreover, systemic 21-day treatment with vortioxetine, a novel multimodal antidepressant, successfully reversed depression-like behaviors and normalized some molecular changes, including that of the norepinephrine transporter in the medial prefrontal cortex, vesicular monoamine transporter 2 in nucleus accumbens core, and serotonin transporter in amygdala. Vortioxetine 41-53 solute carrier family 18 (vesicular monoamine), member 2 Mus musculus 259-292 32534176-0 2021 Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients. Vortioxetine 10-22 brain derived neurotrophic factor Homo sapiens 50-54 32534176-4 2021 Since vortioxetine has a multimodal mechanism of action, it is expected to have a greater effect on circulatory BDNF concentration, compared to conventional antidepressants. Vortioxetine 6-18 brain derived neurotrophic factor Homo sapiens 112-116 32534176-5 2021 This longitudinal study aimed to explore and compare the effects of 4-weeks of treatment with vortioxetine and escitalopram on plasma BDNF and platelet 5-HT concentration in patients with major depressive disorder (MDD). Vortioxetine 94-106 brain derived neurotrophic factor Homo sapiens 134-138 32534176-6 2021 The results revealed that vortioxetine significantly increased plasma BDNF concentration (p = .018) and significantly decreased platelet 5-HT concentration (p < .001). Vortioxetine 26-38 brain derived neurotrophic factor Homo sapiens 70-74 33572981-3 2021 A member of a novel class of antidepressants, vortioxetine, which is a serotonin partial agonist reuptake inhibitor (SPARI), also exhibits a higher affinity for serotonin transporter, serotonin receptors type 1A (5-HT1AR) and type 3 (5-HT3R), and 5-HT7R. Vortioxetine 46-58 solute carrier family 6 member 4 Homo sapiens 161-182 33422821-1 2021 BACKGROUND: To assess the effect of insulin resistance (IR) on treatment response to the antidepressant, vortioxetine, in patients with Major Depressive Disorder (MDD). Vortioxetine 105-117 insulin Homo sapiens 36-43 33572981-3 2021 A member of a novel class of antidepressants, vortioxetine, which is a serotonin partial agonist reuptake inhibitor (SPARI), also exhibits a higher affinity for serotonin transporter, serotonin receptors type 1A (5-HT1AR) and type 3 (5-HT3R), and 5-HT7R. Vortioxetine 46-58 5-hydroxytryptamine receptor 3A Homo sapiens 234-240 33572981-10 2021 These results indicate that chronic administration of vortioxetine, escitalopram, and lurasidone generate downregulation of 5-HT7R in the thalamus; however, the direct inhibition of 5-HT7R associated with vortioxetine and lurasidone generates more rapid downregulation than the indirect elevation of the extracellular serotonin level via serotonin transporter inhibition by escitalopram. Vortioxetine 54-66 solute carrier family 6 member 4 Homo sapiens 338-359 32750222-0 2020 Vortioxetine induces apoptosis and autophagy of gastric cancer AGS cells via the PI3K/AKT pathway. Vortioxetine 0-12 AKT serine/threonine kinase 1 Homo sapiens 86-89 32599653-0 2021 Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles through Population Pharmacokinetic Analysis of Vortioxetine. Vortioxetine 124-136 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 48-54 32599653-3 2021 Vortioxetine is metabolized to its major metabolite, Lu AA34443, primarily via CYP2D6. Vortioxetine 0-12 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 79-85 32599653-4 2021 The aim of this study was to quantify the in vivo CYP2D6 activity of different CYP2D6 alleles and genotypes through population pharmacokinetic (popPK) modelling of vortioxetine and Lu AA34443. Vortioxetine 164-176 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 50-56 32599653-4 2021 The aim of this study was to quantify the in vivo CYP2D6 activity of different CYP2D6 alleles and genotypes through population pharmacokinetic (popPK) modelling of vortioxetine and Lu AA34443. Vortioxetine 164-176 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 79-85 33199100-1 2021 We have previously reported that vortioxetine, unlike the selective serotonin reuptake inhibitor fluoxetine, produces a rapid increase of dendritic spine number and Brain Derived Neurotrophic Factor (BDNF)-associated formation of synapses with mitochondrial support in the rat hippocampal CA1 and dentate gyrus. Vortioxetine 33-45 brain-derived neurotrophic factor Rattus norvegicus 165-198 33199100-1 2021 We have previously reported that vortioxetine, unlike the selective serotonin reuptake inhibitor fluoxetine, produces a rapid increase of dendritic spine number and Brain Derived Neurotrophic Factor (BDNF)-associated formation of synapses with mitochondrial support in the rat hippocampal CA1 and dentate gyrus. Vortioxetine 33-45 brain-derived neurotrophic factor Rattus norvegicus 200-204 33199100-6 2021 Our results showed that vortioxetine significantly increased the number of ramified (resting) microglia and astrocytes accompanied by VEGF level elevation, whereas fluoxetine had no effect after 7 days treatment on these measures. Vortioxetine 24-36 vascular endothelial growth factor A Rattus norvegicus 134-138 32992247-0 2020 Design, synthesis and biological evaluation of vortioxetine derivatives as new COX-1/2 inhibitors in human monocytes. Vortioxetine 47-59 mitochondrially encoded cytochrome c oxidase I Homo sapiens 79-86 32750222-1 2020 Vortioxetine is a potent antagonist of the 5-hydroxytryptamine (5-HT) receptor and serotonin transporter (SERT), and has been reported to function as an antidepressant for treatment of major depressive disorder (MDD). Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 83-104 32750222-1 2020 Vortioxetine is a potent antagonist of the 5-hydroxytryptamine (5-HT) receptor and serotonin transporter (SERT), and has been reported to function as an antidepressant for treatment of major depressive disorder (MDD). Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 106-110 32750222-7 2020 Additionally, vortioxetine could induce apoptosis and autophagy by increasing the levels of Bax, active caspase-3/-9, Beclin-1 and Light Chain 3 (LC3), as well as downregulating Bcl-2 and P62. Vortioxetine 14-26 BCL2 associated X, apoptosis regulator Homo sapiens 92-95 32750222-7 2020 Additionally, vortioxetine could induce apoptosis and autophagy by increasing the levels of Bax, active caspase-3/-9, Beclin-1 and Light Chain 3 (LC3), as well as downregulating Bcl-2 and P62. Vortioxetine 14-26 caspase 3 Homo sapiens 104-116 32750222-7 2020 Additionally, vortioxetine could induce apoptosis and autophagy by increasing the levels of Bax, active caspase-3/-9, Beclin-1 and Light Chain 3 (LC3), as well as downregulating Bcl-2 and P62. Vortioxetine 14-26 beclin 1 Homo sapiens 118-126 32750222-7 2020 Additionally, vortioxetine could induce apoptosis and autophagy by increasing the levels of Bax, active caspase-3/-9, Beclin-1 and Light Chain 3 (LC3), as well as downregulating Bcl-2 and P62. Vortioxetine 14-26 microtubule associated protein 1 light chain 3 alpha Homo sapiens 131-144 32750222-7 2020 Additionally, vortioxetine could induce apoptosis and autophagy by increasing the levels of Bax, active caspase-3/-9, Beclin-1 and Light Chain 3 (LC3), as well as downregulating Bcl-2 and P62. Vortioxetine 14-26 microtubule associated protein 1 light chain 3 alpha Homo sapiens 146-149 32750222-7 2020 Additionally, vortioxetine could induce apoptosis and autophagy by increasing the levels of Bax, active caspase-3/-9, Beclin-1 and Light Chain 3 (LC3), as well as downregulating Bcl-2 and P62. Vortioxetine 14-26 BCL2 apoptosis regulator Homo sapiens 178-183 32750222-7 2020 Additionally, vortioxetine could induce apoptosis and autophagy by increasing the levels of Bax, active caspase-3/-9, Beclin-1 and Light Chain 3 (LC3), as well as downregulating Bcl-2 and P62. Vortioxetine 14-26 nucleoporin 62 Homo sapiens 188-191 32750222-8 2020 Further investigation indicated that vortioxetine regulated apoptosis and autophagy through activation of the PI3K/AKT pathway. Vortioxetine 37-49 AKT serine/threonine kinase 1 Homo sapiens 115-118 32750222-9 2020 Taken together, our data suggest that vortioxetine has cytotoxic effects against GC AGS cells by inhibiting proliferation, invasion and migration, as well as by inducing apoptosis and autophagy through the PI3K/AKT pathway. Vortioxetine 38-50 AKT serine/threonine kinase 1 Homo sapiens 211-214 31953648-10 2020 Interestingly, we found a significant increase in the expression levels of PSD95, SYP, and SYT1 in the 5xFAD mice after vortioxetine treatment compared with the control group. Vortioxetine 120-132 discs large MAGUK scaffold protein 4 Mus musculus 75-80 32765787-1 2020 Effects of Vortioxetine on the expression of brain-derived neurotrophic factor (BDNF) and tyrosine kinase B (Trk B) in hippocampus of depressive rats were investigated. Vortioxetine 11-23 brain-derived neurotrophic factor Rattus norvegicus 45-78 32765787-1 2020 Effects of Vortioxetine on the expression of brain-derived neurotrophic factor (BDNF) and tyrosine kinase B (Trk B) in hippocampus of depressive rats were investigated. Vortioxetine 11-23 brain-derived neurotrophic factor Rattus norvegicus 80-84 32765787-1 2020 Effects of Vortioxetine on the expression of brain-derived neurotrophic factor (BDNF) and tyrosine kinase B (Trk B) in hippocampus of depressive rats were investigated. Vortioxetine 11-23 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 90-107 32765787-1 2020 Effects of Vortioxetine on the expression of brain-derived neurotrophic factor (BDNF) and tyrosine kinase B (Trk B) in hippocampus of depressive rats were investigated. Vortioxetine 11-23 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 109-114 32765787-8 2020 Expression of BDNF and Trk B in the Vortioxetine group was significantly higher than that in the model control group (P<0.05), but lower than that of the normal control group (P<0.05). Vortioxetine 36-48 brain-derived neurotrophic factor Rattus norvegicus 14-18 32765787-8 2020 Expression of BDNF and Trk B in the Vortioxetine group was significantly higher than that in the model control group (P<0.05), but lower than that of the normal control group (P<0.05). Vortioxetine 36-48 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 23-28 32765787-10 2020 Vortioxetine can increase the expression of BDNF and Trk B in depressive rats and alleviate their depressive behavior. Vortioxetine 0-12 brain-derived neurotrophic factor Rattus norvegicus 44-48 32765787-10 2020 Vortioxetine can increase the expression of BDNF and Trk B in depressive rats and alleviate their depressive behavior. Vortioxetine 0-12 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 53-58 32922315-13 2020 Vortioxetine treatment significantly increased BDNF and attenuated IGF-1 serum concentrations, improved all psychopathological and neuropsychological parameters and functioning. Vortioxetine 0-12 brain derived neurotrophic factor Homo sapiens 47-51 32922315-13 2020 Vortioxetine treatment significantly increased BDNF and attenuated IGF-1 serum concentrations, improved all psychopathological and neuropsychological parameters and functioning. Vortioxetine 0-12 insulin like growth factor 1 Homo sapiens 67-72 32384884-0 2020 Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study. Vortioxetine 165-177 insulin like growth factor 1 Homo sapiens 6-34 32384884-12 2020 Vortioxetine treatment significantly attenuated IGF-1 levels and improved all psychopathological, neuropsychological parameters. Vortioxetine 0-12 insulin like growth factor 1 Homo sapiens 48-53 32384884-14 2020 We assume that the activity of the cerebral-hepatic axis increases in response to insufficient IGF-1 brain expression in MDD patients, whereas, vortioxetine treatment restores cerebral IGF-1 concentrations and, consequently, decreases its compensatory production by the liver. Vortioxetine 144-156 insulin like growth factor 1 Homo sapiens 185-190 31953648-10 2020 Interestingly, we found a significant increase in the expression levels of PSD95, SYP, and SYT1 in the 5xFAD mice after vortioxetine treatment compared with the control group. Vortioxetine 120-132 synaptophysin Mus musculus 82-85 31953648-10 2020 Interestingly, we found a significant increase in the expression levels of PSD95, SYP, and SYT1 in the 5xFAD mice after vortioxetine treatment compared with the control group. Vortioxetine 120-132 synaptotagmin I Mus musculus 91-95 31468969-5 2019 Vortioxetine (10 mg/kg) occupancy (%) was 84 +- 1 for SERT, 31 +- 12 for 5-HT1A, and 80 +- 5 for 5-HT1B in brain at 110 min postinjection, and serum oxytocin was 24% lower (p < 0.01) in vortioxetine-treated mice. Vortioxetine 0-12 5-hydroxytryptamine (serotonin) receptor 1B Mus musculus 97-103 31678343-1 2020 The antidepressant drug vortioxetine has a multimodal action modulating neurotransmission through inhibition of the serotonin transporter and modulation of serotonin receptors. Vortioxetine 24-36 solute carrier family 6 member 4 Homo sapiens 116-137 31468969-1 2019 Vortioxetine is a multimodal antidepressant with agonist activity at serotonin (5-HT)1A and 5-HT1B receptors that blocks the 5-HT transporter (SERT). Vortioxetine 0-12 5-hydroxytryptamine (serotonin) receptor 1B Mus musculus 92-98 31835640-0 2019 Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT1A Receptor with 5-HT3 Receptor Inhibition in Rats. Vortioxetine 0-12 5-hydroxytryptamine receptor 3A Rattus norvegicus 118-132 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 104-125 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 127-130 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 5-hydroxytryptamine receptor 3A Homo sapiens 146-151 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 5-hydroxytryptamine receptor 3A Homo sapiens 153-159 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 5-hydroxytryptamine receptor 7 Homo sapiens 169-174 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 5-hydroxytryptamine receptor 7 Homo sapiens 176-182 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 227-233 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 235-242 31835640-2 2019 Vortioxetine has a lower affinity to 5-HT1AR and 5-HT7R in rats compared with humans, but several behavior studies have demonstrated its powerful antidepressant-like actions. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 37-44 31835640-2 2019 Vortioxetine has a lower affinity to 5-HT1AR and 5-HT7R in rats compared with humans, but several behavior studies have demonstrated its powerful antidepressant-like actions. Vortioxetine 0-12 5-hydroxytryptamine receptor 7 Homo sapiens 49-55 31835640-8 2019 These demonstrations, the desensitization of 5-HT1AR with the inhibition of 5-HT3R (without 5-HT3R desensitization), at least partially, contribute to the multimodal antidepressant action of vortioxetine in rats. Vortioxetine 191-203 5-hydroxytryptamine receptor 1A Homo sapiens 45-52 31835640-8 2019 These demonstrations, the desensitization of 5-HT1AR with the inhibition of 5-HT3R (without 5-HT3R desensitization), at least partially, contribute to the multimodal antidepressant action of vortioxetine in rats. Vortioxetine 191-203 5-hydroxytryptamine receptor 3A Rattus norvegicus 76-82 31468969-1 2019 Vortioxetine is a multimodal antidepressant with agonist activity at serotonin (5-HT)1A and 5-HT1B receptors that blocks the 5-HT transporter (SERT). Vortioxetine 0-12 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 125-141 31468969-1 2019 Vortioxetine is a multimodal antidepressant with agonist activity at serotonin (5-HT)1A and 5-HT1B receptors that blocks the 5-HT transporter (SERT). Vortioxetine 0-12 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 143-147 31468969-3 2019 We hypothesized that vortioxetine through its actions at SERT and 5-HT1A could improve BTBR sociability and via 5-HT1B could reduce burying better than sertraline, a selective SERT blocker. Vortioxetine 21-33 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 57-61 31468969-3 2019 We hypothesized that vortioxetine through its actions at SERT and 5-HT1A could improve BTBR sociability and via 5-HT1B could reduce burying better than sertraline, a selective SERT blocker. Vortioxetine 21-33 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 66-72 31468969-3 2019 We hypothesized that vortioxetine through its actions at SERT and 5-HT1A could improve BTBR sociability and via 5-HT1B could reduce burying better than sertraline, a selective SERT blocker. Vortioxetine 21-33 5-hydroxytryptamine (serotonin) receptor 1B Mus musculus 112-118 31468969-3 2019 We hypothesized that vortioxetine through its actions at SERT and 5-HT1A could improve BTBR sociability and via 5-HT1B could reduce burying better than sertraline, a selective SERT blocker. Vortioxetine 21-33 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 176-180 31468969-5 2019 Vortioxetine (10 mg/kg) occupancy (%) was 84 +- 1 for SERT, 31 +- 12 for 5-HT1A, and 80 +- 5 for 5-HT1B in brain at 110 min postinjection, and serum oxytocin was 24% lower (p < 0.01) in vortioxetine-treated mice. Vortioxetine 0-12 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 54-58 31468969-5 2019 Vortioxetine (10 mg/kg) occupancy (%) was 84 +- 1 for SERT, 31 +- 12 for 5-HT1A, and 80 +- 5 for 5-HT1B in brain at 110 min postinjection, and serum oxytocin was 24% lower (p < 0.01) in vortioxetine-treated mice. Vortioxetine 0-12 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 73-79 31468969-9 2019 Based on vortioxetine occupancy, actions at SERT and/or 5-HT1B are more likely to underlie its behavioral effects than 5-HT1A. Vortioxetine 9-21 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 44-48 31468969-9 2019 Based on vortioxetine occupancy, actions at SERT and/or 5-HT1B are more likely to underlie its behavioral effects than 5-HT1A. Vortioxetine 9-21 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 119-125 31642818-14 2019 The level of BDNF was increased with Vrx in the frontal cortex. Vortioxetine 37-40 brain-derived neurotrophic factor Rattus norvegicus 13-17 30780196-0 2019 Efficacy of vortioxetine combined cognitive behaviour intervention therapy on brain-derived neurotrophic factor level on depressive patients. Vortioxetine 12-24 brain derived neurotrophic factor Homo sapiens 78-111 30780196-1 2019 BACKGROUND: To evaluate the effect of vortioxetine combined with cognitive behaviour intervention on the level of brain-derived neurotrophic factor (BDNF) in the serum of patients with depression and its therapeutic effect. Vortioxetine 38-50 brain derived neurotrophic factor Homo sapiens 114-147 30780196-1 2019 BACKGROUND: To evaluate the effect of vortioxetine combined with cognitive behaviour intervention on the level of brain-derived neurotrophic factor (BDNF) in the serum of patients with depression and its therapeutic effect. Vortioxetine 38-50 brain derived neurotrophic factor Homo sapiens 149-153 30194544-25 2019 One third of inpatients and one half of outpatients had a significant therapeutic response to trazadone by the end of the first week with the remainder of patients responding in 2-4 weeks of therapy.Vortioxetine is a novel antidepressant classified by the World Health Organization as a N06AX antidepressant that was derived from studies targeting the combination of direct serotonin transporter inhibition and 5-HT1A receptor modulation leading to rapid desensitization of the somatodendritic 5-HT1A autoreceptors and activation of the postsynaptic 5-HT1A receptors. Vortioxetine 199-211 5-hydroxytryptamine receptor 1A Homo sapiens 494-500 31314843-1 2019 Vortioxetine is a multimodal antidepressant agent that modulates 5-HT receptors and inhibits the serotonin transporter. Vortioxetine 0-12 solute carrier family 6 member 4 Rattus norvegicus 97-118 30735803-4 2019 We found that prolonged vortioxetine administration significantly increased total Bdnf expression in the dorsal and ventral hippocampus of adult male rats and affected the stress-induced modulation of the immediate early genes Arc and Zif268, mainly in the ventral sub-region. Vortioxetine 24-36 brain-derived neurotrophic factor Rattus norvegicus 82-86 30735803-4 2019 We found that prolonged vortioxetine administration significantly increased total Bdnf expression in the dorsal and ventral hippocampus of adult male rats and affected the stress-induced modulation of the immediate early genes Arc and Zif268, mainly in the ventral sub-region. Vortioxetine 24-36 nucleolar protein 3 Rattus norvegicus 227-230 30735803-4 2019 We found that prolonged vortioxetine administration significantly increased total Bdnf expression in the dorsal and ventral hippocampus of adult male rats and affected the stress-induced modulation of the immediate early genes Arc and Zif268, mainly in the ventral sub-region. Vortioxetine 24-36 early growth response 1 Rattus norvegicus 235-241 30476727-0 2019 abcb1ab p-glycoprotein is involved in the uptake of the novel antidepressant vortioxetine into the brain of mice. Vortioxetine 77-89 ATP-binding cassette, sub-family B (MDR/TAP), member 1B Mus musculus 0-5 30476727-0 2019 abcb1ab p-glycoprotein is involved in the uptake of the novel antidepressant vortioxetine into the brain of mice. Vortioxetine 77-89 phosphoglycolate phosphatase Mus musculus 8-22 30476727-4 2019 In the current study, we tested the P-gp substrate status for the antidepressant vortioxetine using double abcb1ab knock-out (KO) mice. Vortioxetine 81-93 phosphoglycolate phosphatase Mus musculus 36-40 30476727-7 2019 The results of our study provide conclusive in-vivo evidence that in mice vortioxetine"s brain bioavailability is P-gp dependent, expanding previous findings on this topic. Vortioxetine 74-86 phosphoglycolate phosphatase Mus musculus 114-118 30457395-6 2019 Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Vortioxetine 16-28 solute carrier family 6 member 4 Homo sapiens 79-83 30457395-6 2019 Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Vortioxetine 16-28 5-hydroxytryptamine receptor 1A Homo sapiens 107-112 30457395-7 2019 Functional studies show that vortioxetine acts as a SERT blocker, a 5-HT3, 5-HT7 receptor antagonist, and a 5-HT1A receptor agonist. Vortioxetine 29-41 solute carrier family 6 member 4 Homo sapiens 52-56 30457395-7 2019 Functional studies show that vortioxetine acts as a SERT blocker, a 5-HT3, 5-HT7 receptor antagonist, and a 5-HT1A receptor agonist. Vortioxetine 29-41 5-hydroxytryptamine receptor 1A Homo sapiens 108-123 31293421-0 2019 Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Abeta1-42 Oligomers in Mice: A Key Role of Transforming Growth Factor-beta1. Vortioxetine 15-27 transforming growth factor, beta 1 Mus musculus 136-168 31293421-9 2019 Fluoxetine and vortioxetine completely rescued hippocampal TGF-beta1 levels in Abeta-injected mice as well as synaptophysin and PSD-95 levels. Vortioxetine 15-27 transforming growth factor, beta 1 Mus musculus 59-68 31293421-9 2019 Fluoxetine and vortioxetine completely rescued hippocampal TGF-beta1 levels in Abeta-injected mice as well as synaptophysin and PSD-95 levels. Vortioxetine 15-27 synaptophysin Mus musculus 110-123 31293421-10 2019 This is the first evidence that a chronic treatment with fluoxetine or vortioxetine can prevent both cognitive deficits and depressive-like phenotype in a non-transgenic animal model of AD with a key contribution of TGF-beta1. Vortioxetine 71-83 transforming growth factor, beta 1 Mus musculus 216-225 30317998-1 2019 BACKGROUND: Vortioxetine is a multimodal antidepressant drug with combined effects on SERT as an inhibitor, 5-HT1A as agonist and 5-HT3A as an antagonist. Vortioxetine 12-24 solute carrier family 6 member 4 Homo sapiens 86-90 30317998-1 2019 BACKGROUND: Vortioxetine is a multimodal antidepressant drug with combined effects on SERT as an inhibitor, 5-HT1A as agonist and 5-HT3A as an antagonist. Vortioxetine 12-24 5-hydroxytryptamine receptor 1A Homo sapiens 108-114 30317998-1 2019 BACKGROUND: Vortioxetine is a multimodal antidepressant drug with combined effects on SERT as an inhibitor, 5-HT1A as agonist and 5-HT3A as an antagonist. Vortioxetine 12-24 5-hydroxytryptamine receptor 3A Homo sapiens 130-136 30317998-2 2019 Series of vortioxetine analogs have been reported as multi antidepressant compounds and they block serotonin transport into the neuronal cells, activate the postsynaptic 5-HT1A receptors and eliminate the low activity of 5-HT3A receptors. Vortioxetine 10-22 5-hydroxytryptamine receptor 1A Homo sapiens 170-176 30317998-2 2019 Series of vortioxetine analogs have been reported as multi antidepressant compounds and they block serotonin transport into the neuronal cells, activate the postsynaptic 5-HT1A receptors and eliminate the low activity of 5-HT3A receptors. Vortioxetine 10-22 5-hydroxytryptamine receptor 3A Homo sapiens 221-227 30457395-6 2019 Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Vortioxetine 16-28 solute carrier family 6 member 4 Homo sapiens 56-77 30194544-25 2019 One third of inpatients and one half of outpatients had a significant therapeutic response to trazadone by the end of the first week with the remainder of patients responding in 2-4 weeks of therapy.Vortioxetine is a novel antidepressant classified by the World Health Organization as a N06AX antidepressant that was derived from studies targeting the combination of direct serotonin transporter inhibition and 5-HT1A receptor modulation leading to rapid desensitization of the somatodendritic 5-HT1A autoreceptors and activation of the postsynaptic 5-HT1A receptors. Vortioxetine 199-211 solute carrier family 6 member 4 Homo sapiens 374-395 30194544-25 2019 One third of inpatients and one half of outpatients had a significant therapeutic response to trazadone by the end of the first week with the remainder of patients responding in 2-4 weeks of therapy.Vortioxetine is a novel antidepressant classified by the World Health Organization as a N06AX antidepressant that was derived from studies targeting the combination of direct serotonin transporter inhibition and 5-HT1A receptor modulation leading to rapid desensitization of the somatodendritic 5-HT1A autoreceptors and activation of the postsynaptic 5-HT1A receptors. Vortioxetine 199-211 5-hydroxytryptamine receptor 1A Homo sapiens 411-417 30194544-25 2019 One third of inpatients and one half of outpatients had a significant therapeutic response to trazadone by the end of the first week with the remainder of patients responding in 2-4 weeks of therapy.Vortioxetine is a novel antidepressant classified by the World Health Organization as a N06AX antidepressant that was derived from studies targeting the combination of direct serotonin transporter inhibition and 5-HT1A receptor modulation leading to rapid desensitization of the somatodendritic 5-HT1A autoreceptors and activation of the postsynaptic 5-HT1A receptors. Vortioxetine 199-211 5-hydroxytryptamine receptor 1A Homo sapiens 494-500 30194544-29 2019 The maximum dose of vortioxetine is 20 mg daily with improvement in symptoms of depression noted at 2 weeks with a full therapeutic effect observed at 4-6 weeks.Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist. Vortioxetine 20-32 5-hydroxytryptamine receptor 1A Homo sapiens 220-226 29514282-0 2018 A Critical Role of Mitochondria in BDNF-Associated Synaptic Plasticity After One-Week Vortioxetine Treatment. Vortioxetine 86-98 brain-derived neurotrophic factor Rattus norvegicus 35-39 29933036-0 2018 Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. Vortioxetine 11-23 brain-derived neurotrophic factor Rattus norvegicus 91-95 29933036-7 2018 In conclusion, vortioxetine, but not fluoxetine, increased hippocampal BDNF levels in rats subject to CUMS. Vortioxetine 15-27 brain-derived neurotrophic factor Rattus norvegicus 71-75 30257860-0 2018 Modeling and Mutational Analysis of the Binding Mode for the Multimodal Antidepressant Drug Vortioxetine to the Human 5-HT3A Receptor. Vortioxetine 92-104 5-hydroxytryptamine receptor 3A Homo sapiens 118-124 30257860-6 2018 We have investigated the binding mode of vortioxetine at the human 5-HT3A receptor through computational and in vitro experiments to provide insight into the molecular mechanisms behind the unique pharmacological profile of the drug. Vortioxetine 41-53 5-hydroxytryptamine receptor 3A Homo sapiens 67-73 29274875-0 2018 The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: An in vitro study in rat hippocampus slices. Vortioxetine 30-42 5-hydroxytryptamine receptor 3A Rattus norvegicus 97-111 29274875-1 2018 The multimodal antidepressant vortioxetine is thought to mediate its pharmacological effects via 5-HT1A receptor agonism, 5-HT1B receptor partial agonism, 5-HT1D, 5-HT3, 5-HT7 receptor antagonism and 5-HT transporter inhibition. Vortioxetine 30-42 5-hydroxytryptamine receptor 1D Rattus norvegicus 155-161 29274875-2 2018 Here we studied vortioxetine"s functional effects across species (canine, mouse, rat, guinea pig and human) in cellular assays with heterologous expression of 5-HT3A receptors (in Xenopus oocytes and HEK-293 cells) and in mouse neuroblastoma N1E-115 cells with endogenous expression of 5-HT3A receptors. Vortioxetine 16-28 5-hydroxytryptamine receptor 3A Cavia porcellus 159-165 29274875-2 2018 Here we studied vortioxetine"s functional effects across species (canine, mouse, rat, guinea pig and human) in cellular assays with heterologous expression of 5-HT3A receptors (in Xenopus oocytes and HEK-293 cells) and in mouse neuroblastoma N1E-115 cells with endogenous expression of 5-HT3A receptors. Vortioxetine 16-28 5-hydroxytryptamine (serotonin) receptor 3A Mus musculus 286-292 29274875-3 2018 Furthermore, we studied the effects of vortioxetine on activity of CA1 Stratum Radiatum interneurons in rat hippocampus slices using current- and voltage-clamping methods. Vortioxetine 39-51 carbonic anhydrase 1 Rattus norvegicus 67-70 29274875-5 2018 Whereas, both vortioxetine and the 5-HT3 receptor antagonist ondansetron potently antagonized 5-HT-induced currents in the cellular assays, vortioxetine had a slower off-rate than ondansetron in oocytes expressing 5-HT3A receptors. Vortioxetine 140-152 5-hydroxytryptamine receptor 3A Cavia porcellus 214-220 29274875-7 2018 Vortioxetine had the highest potency at rat and the lowest potency at guinea pig 5-HT3A receptors. Vortioxetine 0-12 5-hydroxytryptamine receptor 3A Cavia porcellus 81-87 29274875-8 2018 Finally, in 5-HT3 receptor-expressing GABAergic interneurons from the CA1 stratum radiatum, vortioxetine and ondansetron blocked depolarizations induced by superfusion of either 5-HT or the 5-HT3 receptor agonist mCPBG. Vortioxetine 92-104 5-hydroxytryptamine receptor 3A Rattus norvegicus 12-26 29274875-8 2018 Finally, in 5-HT3 receptor-expressing GABAergic interneurons from the CA1 stratum radiatum, vortioxetine and ondansetron blocked depolarizations induced by superfusion of either 5-HT or the 5-HT3 receptor agonist mCPBG. Vortioxetine 92-104 carbonic anhydrase 1 Rattus norvegicus 70-73 29274875-8 2018 Finally, in 5-HT3 receptor-expressing GABAergic interneurons from the CA1 stratum radiatum, vortioxetine and ondansetron blocked depolarizations induced by superfusion of either 5-HT or the 5-HT3 receptor agonist mCPBG. Vortioxetine 92-104 5-hydroxytryptamine receptor 3A Rattus norvegicus 190-204 29274875-9 2018 Taken together, these data add to a growing literature supporting the idea that vortioxetine may inhibit GABAergic neurotransmission in some brain regions via a 5-HT3 receptor antagonism-dependent mechanism and thereby disinhibit pyramidal neurons and enhance glutamatergic signaling. Vortioxetine 80-92 5-hydroxytryptamine receptor 3A Rattus norvegicus 161-175 29189941-11 2018 Pharmacodynamic studies demonstrated that vortioxetine achieved high levels of serotonin transporter occupancy in relevant brain areas, affected neurotransmitter levels in the cerebrospinal fluid, and modified abnormal resting state networks in the brain over the therapeutic dose range. Vortioxetine 42-54 solute carrier family 6 member 4 Homo sapiens 79-100 29514282-3 2018 Taking into consideration that vortioxetine increases spine number and dendritic branching in hippocampus CA1 faster than fluoxetine, we hypothesize that new spines induced by vortioxetine can rapidly form functional synapses by mitochondrial support, accompanied by increased brain-derived neurotrophic factor signaling. Vortioxetine 31-43 carbonic anhydrase 1 Rattus norvegicus 106-109 29514282-3 2018 Taking into consideration that vortioxetine increases spine number and dendritic branching in hippocampus CA1 faster than fluoxetine, we hypothesize that new spines induced by vortioxetine can rapidly form functional synapses by mitochondrial support, accompanied by increased brain-derived neurotrophic factor signaling. Vortioxetine 31-43 brain-derived neurotrophic factor Rattus norvegicus 277-310 29514282-3 2018 Taking into consideration that vortioxetine increases spine number and dendritic branching in hippocampus CA1 faster than fluoxetine, we hypothesize that new spines induced by vortioxetine can rapidly form functional synapses by mitochondrial support, accompanied by increased brain-derived neurotrophic factor signaling. Vortioxetine 176-188 carbonic anhydrase 1 Rattus norvegicus 106-109 29514282-3 2018 Taking into consideration that vortioxetine increases spine number and dendritic branching in hippocampus CA1 faster than fluoxetine, we hypothesize that new spines induced by vortioxetine can rapidly form functional synapses by mitochondrial support, accompanied by increased brain-derived neurotrophic factor signaling. Vortioxetine 176-188 brain-derived neurotrophic factor Rattus norvegicus 277-310 29514282-9 2018 BDNF levels in hippocampus DG and CA1 were significantly higher after vortioxetine treatment. Vortioxetine 70-82 brain-derived neurotrophic factor Rattus norvegicus 0-4 29514282-10 2018 Gene expression levels of Rac1 after vortioxetine treatment were significantly increased. Vortioxetine 37-49 Rac family small GTPase 1 Rattus norvegicus 26-30 29514282-15 2018 Rapid changes in BDNF levels and synaptic/mitochondria plasticity of hippocampus following vortioxetine compared with fluoxetine may be ascribed to vortioxetine"s modulation of serotonin receptors. Vortioxetine 91-103 brain-derived neurotrophic factor Rattus norvegicus 17-21 29514282-15 2018 Rapid changes in BDNF levels and synaptic/mitochondria plasticity of hippocampus following vortioxetine compared with fluoxetine may be ascribed to vortioxetine"s modulation of serotonin receptors. Vortioxetine 148-160 brain-derived neurotrophic factor Rattus norvegicus 17-21 29269186-10 2018 These observations support the hypothesis that vortioxetine"s antidepressant activity may involve mechanisms beyond SERT inhibition. Vortioxetine 47-59 solute carrier family 6 member 4 Rattus norvegicus 116-120 29174531-8 2018 This strategy has been incorporated into two new multi-target antidepressant drugs, vilazodone and vortioxetine, which combine 5-HT reuptake inhibition and partial agonism at 5-HT1A receptors. Vortioxetine 99-111 5-hydroxytryptamine receptor 1A Homo sapiens 175-181 29269186-6 2018 Vortioxetine reduced TRP depletion-induced increases of serum corticosterone, aldosterone, IL-6 and N-methyl-d-aspartate and alpha7-nicotinic acetylcholine receptor expression in the amygdala and hippocampus, respectively. Vortioxetine 0-12 interleukin 6 Rattus norvegicus 91-95 29057467-6 2018 KEY RESULTS: Vortioxetine significantly reduced the PMA-induced oxidative burst in monocytes and in macrophages (M1 and M2), causing a concomitant shift of macrophages from the M1 to the M2 phenotype, demonstrated by a significant decrease in the expression of the surface marker CD86 and an increase in CD206. Vortioxetine 13-25 mannose receptor C-type 1 Homo sapiens 304-309 29057467-7 2018 Moreover, treatment of monocytes with vortioxetine rendered macrophages derived from this population less sensitive to PMA, as it reduced the oxidative burst, NF-kB translocation, TNFalpha release and expression while inducing PPARgamma gene expression. Vortioxetine 38-50 tumor necrosis factor Homo sapiens 180-188 29057467-7 2018 Moreover, treatment of monocytes with vortioxetine rendered macrophages derived from this population less sensitive to PMA, as it reduced the oxidative burst, NF-kB translocation, TNFalpha release and expression while inducing PPARgamma gene expression. Vortioxetine 38-50 peroxisome proliferator activated receptor gamma Homo sapiens 227-236 29102760-8 2018 Vortioxetine administration for 14 days increased the N-methyl-d-aspartate (NMDA)-, but not alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-evoked responses of CA3 pyramidal neurons. Vortioxetine 0-12 carbonic anhydrase 3 Rattus norvegicus 176-179 29104073-1 2018 The antidepressant vortioxetine exerts its effects via modulation of several serotonin (5-HT) receptors and inhibition of the 5-HT transporter (SERT). Vortioxetine 19-31 solute carrier family 6 member 4 Rattus norvegicus 126-142 29104073-1 2018 The antidepressant vortioxetine exerts its effects via modulation of several serotonin (5-HT) receptors and inhibition of the 5-HT transporter (SERT). Vortioxetine 19-31 solute carrier family 6 member 4 Rattus norvegicus 144-148 28692076-6 2017 A novel antidepressant, with a multimodal mechanism of action that combines the classical inhibition of serotonin transporter (SERT) with the modulation of serotonin receptor activity, is vortioxetine. Vortioxetine 188-200 solute carrier family 6 member 4 Homo sapiens 104-125 30289053-1 2018 Vortioxetine is a multimodal antidepressant that potently antagonizes 5-HT3 serotonin receptors, inhibits the high-affinity serotonin transporter, activates 5-HT1A and 5-HT1B receptors, and antagonizes 5-HT1D and 5-HT7 receptors. Vortioxetine 0-12 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 157-208 28677828-5 2017 It is assumed that vortioxetine"s antidepressant action is related to a direct modulation of serotonergic receptor activity and inhibition of the serotonin transporter. Vortioxetine 19-31 solute carrier family 6 member 4 Homo sapiens 146-167 28407315-5 2017 Sustained vortioxetine or fluoxetine (at doses aimed to fully occupy serotonin transporter via food or drinking water for at least 14 days) reduced levels of the excitotoxin quinolinic acid (QUIN) in various brain regions in all rats. Vortioxetine 10-22 solute carrier family 6 member 4 Rattus norvegicus 69-90 28272863-0 2017 Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse. Vortioxetine 64-76 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 99-103 28272863-3 2017 Recently, agents have been developed, including vortioxetine (Trintellix), that augment SERT blockade with interactions at other targets. Vortioxetine 48-60 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 88-92 28272863-3 2017 Recently, agents have been developed, including vortioxetine (Trintellix), that augment SERT blockade with interactions at other targets. Vortioxetine 62-72 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 88-92 28272863-4 2017 At therapeutic doses, vortioxetine interacts with SERT as well as 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors. Vortioxetine 22-34 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 50-54 28272863-4 2017 At therapeutic doses, vortioxetine interacts with SERT as well as 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors. Vortioxetine 22-34 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 66-72 28272863-4 2017 At therapeutic doses, vortioxetine interacts with SERT as well as 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors. Vortioxetine 22-34 5-hydroxytryptamine (serotonin) receptor 1B Mus musculus 74-80 28272863-5 2017 We assessed the SERT-dependency of vortioxetine action using the SERT Met172 mouse model, which disrupts high-affinity interactions of many antidepressants with the transporter. Vortioxetine 35-47 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 16-20 28272863-5 2017 We assessed the SERT-dependency of vortioxetine action using the SERT Met172 mouse model, which disrupts high-affinity interactions of many antidepressants with the transporter. Vortioxetine 35-47 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 65-69 28272863-6 2017 We demonstrate that the SERT Met172 substitution induces an ~19-fold loss in vortioxetine potency for SERT inhibition in midbrain synaptosomes. Vortioxetine 77-89 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 24-28 28272863-6 2017 We demonstrate that the SERT Met172 substitution induces an ~19-fold loss in vortioxetine potency for SERT inhibition in midbrain synaptosomes. Vortioxetine 77-89 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 102-106 28272863-8 2017 Despite reduced interactions with SERT, vortioxetine maintained its ability to enhance mobility in tail suspension and forced swim tests, reduce consumption latency in the novelty induced hypophagia test, and promoted proliferation and survival of subgranular zone hippocampal stem cells. Vortioxetine 40-52 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 34-38 28272863-9 2017 Our findings suggest that the antidepressant actions of vortioxetine may be SERT-independent, and encourage consideration of agents that mimic one or more actions of the drug in the development of improved depression treatments. Vortioxetine 56-68 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 76-80 28692076-6 2017 A novel antidepressant, with a multimodal mechanism of action that combines the classical inhibition of serotonin transporter (SERT) with the modulation of serotonin receptor activity, is vortioxetine. Vortioxetine 188-200 solute carrier family 6 member 4 Homo sapiens 127-131 28109109-0 2017 [Role of cAMP/CREB/BDNF signaling pathway in anti-depressive effect of vortioxetine in mice]. Vortioxetine 71-83 cathelicidin antimicrobial peptide Mus musculus 9-13 27678087-4 2017 In rodent studies, vortioxetine increases glutamate neurotransmission, promotes dendritic branching and spine maturation, and elevates hippocampal expression of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1) at the transcript level. Vortioxetine 19-31 activity regulated cytoskeletal-associated protein Mus musculus 217-227 27678087-6 2017 Chronic (1 month) vortioxetine increased Arc/Arg3.1 protein levels in the cortical synaptosomes of young and middle-aged mice. Vortioxetine 18-30 activity regulated cytoskeletal-associated protein Mus musculus 41-51 27678087-8 2017 Similar effects were detected in cultured rat hippocampal neurons: Acute vortioxetine increased S845 GluA1 phosphorylation without changing S831 GluA1 phosphorylation or the total GluA1 protein level. Vortioxetine 73-85 glutamate ionotropic receptor AMPA type subunit 1 Rattus norvegicus 101-106 27678087-10 2017 In addition, chronic (1 month) vortioxetine, but not fluoxetine, restored the age-associated reduction in Arc/Arg3.1 and c-Fos transcripts in the frontal cortex of middle-aged mice. Vortioxetine 31-43 activity regulated cytoskeletal-associated protein Mus musculus 106-116 27678087-10 2017 In addition, chronic (1 month) vortioxetine, but not fluoxetine, restored the age-associated reduction in Arc/Arg3.1 and c-Fos transcripts in the frontal cortex of middle-aged mice. Vortioxetine 31-43 FBJ osteosarcoma oncogene Mus musculus 121-126 28109109-0 2017 [Role of cAMP/CREB/BDNF signaling pathway in anti-depressive effect of vortioxetine in mice]. Vortioxetine 71-83 cAMP responsive element binding protein 1 Mus musculus 14-18 28109109-0 2017 [Role of cAMP/CREB/BDNF signaling pathway in anti-depressive effect of vortioxetine in mice]. Vortioxetine 71-83 brain derived neurotrophic factor Mus musculus 19-23 28109109-1 2017 OBJECTIVE: To investigate the effects of vortioxetine on cAMP/CREB/BDNF signal pathway. Vortioxetine 41-53 cathelicidin antimicrobial peptide Mus musculus 57-61 28109109-1 2017 OBJECTIVE: To investigate the effects of vortioxetine on cAMP/CREB/BDNF signal pathway. Vortioxetine 41-53 cAMP responsive element binding protein 1 Mus musculus 62-66 28109109-1 2017 OBJECTIVE: To investigate the effects of vortioxetine on cAMP/CREB/BDNF signal pathway. Vortioxetine 41-53 brain derived neurotrophic factor Mus musculus 67-71 28109109-7 2017 Vortioxetine significantly increased the levels of cAMP and promoted the expression of pCREB and BDNF in the hippocampus of the mice (P<0.01). Vortioxetine 0-12 cathelicidin antimicrobial peptide Mus musculus 51-55 28109109-7 2017 Vortioxetine significantly increased the levels of cAMP and promoted the expression of pCREB and BDNF in the hippocampus of the mice (P<0.01). Vortioxetine 0-12 brain derived neurotrophic factor Mus musculus 97-101 28109109-8 2017 CONCLUSION: Vortioxetine improves the behaviors of mice with depression possibly by affecting the cAMP/CREB/BDNF signal pathway. Vortioxetine 12-24 cathelicidin antimicrobial peptide Mus musculus 98-102 28109109-8 2017 CONCLUSION: Vortioxetine improves the behaviors of mice with depression possibly by affecting the cAMP/CREB/BDNF signal pathway. Vortioxetine 12-24 cAMP responsive element binding protein 1 Mus musculus 103-107 28109109-8 2017 CONCLUSION: Vortioxetine improves the behaviors of mice with depression possibly by affecting the cAMP/CREB/BDNF signal pathway. Vortioxetine 12-24 brain derived neurotrophic factor Mus musculus 108-112 27996982-2 2016 Vortioxetine is a multi-modal antidepressant that functions both as serotonin transporter (SERT) inhibitor and as 5-HT3, 5-HT7 and 5-HT1D receptors antagonist, 5-HT1A receptor agonist and 5-HT1B receptor partial agonist. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 68-89 27781949-1 2017 BACKGROUND: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT) transporter inhibitor as well as 5HT3A and 5HT7 receptors antagonist, 5HT1A and 5HT1B receptors partial agonist. Vortioxetine 12-24 5-hydroxytryptamine receptor 1A Homo sapiens 161-176 27781949-1 2017 BACKGROUND: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT) transporter inhibitor as well as 5HT3A and 5HT7 receptors antagonist, 5HT1A and 5HT1B receptors partial agonist. Vortioxetine 26-29 5-hydroxytryptamine receptor 1A Homo sapiens 161-176 27996982-2 2016 Vortioxetine is a multi-modal antidepressant that functions both as serotonin transporter (SERT) inhibitor and as 5-HT3, 5-HT7 and 5-HT1D receptors antagonist, 5-HT1A receptor agonist and 5-HT1B receptor partial agonist. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 91-95 26879252-7 2016 Compared to the SSRIs, vortioxetine is defined as a multimodal antidepressant drug since it is not only a serotonin reuptake inhibitor, but also a 5-HT1D, 5-HT3, 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist and 5-HT1A receptor agonist. Vortioxetine 23-35 5-hydroxytryptamine receptor 1D Homo sapiens 147-153 27106166-1 2016 The antidepressant vortioxetine is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine 19-31 5-hydroxytryptamine receptor 3A Rattus norvegicus 37-44 27106166-1 2016 The antidepressant vortioxetine is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine 19-31 5-hydroxytryptamine receptor 1B Rattus norvegicus 79-85 27106166-1 2016 The antidepressant vortioxetine is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine 19-31 solute carrier family 6 member 4 Rattus norvegicus 157-161 27106166-4 2016 Given its high affinity for 5-HT3-R (Ki = 3.7 nM), selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT3-R blockade. Vortioxetine 116-128 5-hydroxytryptamine receptor 3A Rattus norvegicus 28-35 27106166-4 2016 Given its high affinity for 5-HT3-R (Ki = 3.7 nM), selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT3-R blockade. Vortioxetine 116-128 5-hydroxytryptamine receptor 3A Rattus norvegicus 204-211 26525043-4 2016 One- and two-compartment models were evaluated as structural PK models, and linear and nonlinear (Emax) models were used to describe the relationship between average vortioxetine concentration at steady-state (Cav) and change in MADRS score from baseline (DeltaMADRS). Vortioxetine 166-178 caveolin 2 Homo sapiens 210-213 27089947-4 2016 We employ ultraviolet-induced crosslinking with p-azido-L-phenylalanine (azF) at selected positions in hSERT to map the binding site of imipramine, a prototypical tricyclic antidepressant, and vortioxetine, a novel multimodal antidepressant. Vortioxetine 193-205 AZF1 Homo sapiens 73-76 26700248-0 2016 P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo. Vortioxetine 84-96 phosphoglycolate phosphatase Mus musculus 0-14 26700248-2 2016 In the present study the role of P-gp in transport across the blood-brain barrier (BBB) was investigated with a series of newer antidepressants (levomilnacipran, vilazodone and vortioxetine) and a control substrate (escitalopram) using P-gp knock-out (KO) and P-gp competent wild-type (WT) mice. Vortioxetine 177-189 phosphoglycolate phosphatase Mus musculus 33-37 26702943-2 2016 The multimodal-acting antidepressant vortioxetine is an antagonist at 5-HT3, 5-HT7, and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, an agonist at 5-HT1A receptors, and an inhibitor of the serotonin (5-HT) transporter (SERT) and has pro-cognitive properties. Vortioxetine 37-49 5-hydroxytryptamine receptor 1B Homo sapiens 127-133 26358483-1 2016 Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin transporter (5-HTT). Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 93-99 26358483-1 2016 Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin transporter (5-HTT). Vortioxetine 0-12 5-hydroxytryptamine receptor 1B Homo sapiens 101-107 26358483-1 2016 Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin transporter (5-HTT). Vortioxetine 0-12 5-hydroxytryptamine receptor 1D Homo sapiens 109-115 27235984-8 2016 The main finding was that vortioxetine enhanced plasticity-related gene expression (Mtor, Mglur1, Pkcalpha, Homer3, Spinophilin, and Synapsin3) in the frontal cortex at 8h after a single dose. Vortioxetine 26-38 mechanistic target of rapamycin kinase Rattus norvegicus 84-88 27235984-8 2016 The main finding was that vortioxetine enhanced plasticity-related gene expression (Mtor, Mglur1, Pkcalpha, Homer3, Spinophilin, and Synapsin3) in the frontal cortex at 8h after a single dose. Vortioxetine 26-38 glutamate metabotropic receptor 1 Rattus norvegicus 90-96 27235984-8 2016 The main finding was that vortioxetine enhanced plasticity-related gene expression (Mtor, Mglur1, Pkcalpha, Homer3, Spinophilin, and Synapsin3) in the frontal cortex at 8h after a single dose. Vortioxetine 26-38 protein kinase C, alpha Rattus norvegicus 98-106 27235984-8 2016 The main finding was that vortioxetine enhanced plasticity-related gene expression (Mtor, Mglur1, Pkcalpha, Homer3, Spinophilin, and Synapsin3) in the frontal cortex at 8h after a single dose. Vortioxetine 26-38 homer scaffold protein 3 Rattus norvegicus 108-114 27235984-8 2016 The main finding was that vortioxetine enhanced plasticity-related gene expression (Mtor, Mglur1, Pkcalpha, Homer3, Spinophilin, and Synapsin3) in the frontal cortex at 8h after a single dose. Vortioxetine 26-38 protein phosphatase 1, regulatory subunit 9B Rattus norvegicus 116-127 27235984-8 2016 The main finding was that vortioxetine enhanced plasticity-related gene expression (Mtor, Mglur1, Pkcalpha, Homer3, Spinophilin, and Synapsin3) in the frontal cortex at 8h after a single dose. Vortioxetine 26-38 synapsin III Rattus norvegicus 133-142 27356518-8 2016 Vortioxetine treatment significantly (p < 0.0001; omega = 0.80) decreased platelet 5-HT concentration and significantly (p = 0.004; omega = 0.80) increased plasma BDNF concentration in depressed patients compared to their baseline values. Vortioxetine 0-12 brain derived neurotrophic factor Homo sapiens 166-170 27356518-11 2016 This study is the first to show that, in addition to clinical improvement, 4 weeks of treatment with vortioxetine (5-15 mg daily), decreased platelet 5-HT and increased plasma BDNF concentrations in depressed patients. Vortioxetine 101-113 brain derived neurotrophic factor Homo sapiens 176-180 27050932-4 2016 Vortioxetine (VRX) is a multimodal antidepressant with a unique mechanism of action, by acting as 5-HT3A, 5-HT1D and 5-HT7 receptor antagonist, partial agonist at the 5-HT1A and 5-HT1B receptors and inhibitor at the 5-HT transporter. Vortioxetine 0-12 5-hydroxytryptamine receptor 3A Homo sapiens 98-104 27050932-4 2016 Vortioxetine (VRX) is a multimodal antidepressant with a unique mechanism of action, by acting as 5-HT3A, 5-HT1D and 5-HT7 receptor antagonist, partial agonist at the 5-HT1A and 5-HT1B receptors and inhibitor at the 5-HT transporter. Vortioxetine 14-17 5-hydroxytryptamine receptor 3A Homo sapiens 98-104 26702943-2 2016 The multimodal-acting antidepressant vortioxetine is an antagonist at 5-HT3, 5-HT7, and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, an agonist at 5-HT1A receptors, and an inhibitor of the serotonin (5-HT) transporter (SERT) and has pro-cognitive properties. Vortioxetine 37-49 5-hydroxytryptamine receptor 1A Homo sapiens 159-165 26702943-2 2016 The multimodal-acting antidepressant vortioxetine is an antagonist at 5-HT3, 5-HT7, and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, an agonist at 5-HT1A receptors, and an inhibitor of the serotonin (5-HT) transporter (SERT) and has pro-cognitive properties. Vortioxetine 37-49 solute carrier family 6 member 4 Homo sapiens 231-235 26879252-7 2016 Compared to the SSRIs, vortioxetine is defined as a multimodal antidepressant drug since it is not only a serotonin reuptake inhibitor, but also a 5-HT1D, 5-HT3, 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist and 5-HT1A receptor agonist. Vortioxetine 23-35 5-hydroxytryptamine receptor 1B Homo sapiens 189-195 26879252-7 2016 Compared to the SSRIs, vortioxetine is defined as a multimodal antidepressant drug since it is not only a serotonin reuptake inhibitor, but also a 5-HT1D, 5-HT3, 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist and 5-HT1A receptor agonist. Vortioxetine 23-35 5-hydroxytryptamine receptor 1A Homo sapiens 225-231 26464458-8 2016 Against this background, we feature the novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacipran with regard to their serotonin receptor targets such as the 5-HT1A, 5-HT3 and 5-HT7 which may account for their specific effects on certain symptoms of depression (e.g. cognition and anxiety) as well as a characteristic side-effect profile. Vortioxetine 62-74 5-hydroxytryptamine receptor 1A Homo sapiens 179-185 26389667-0 2015 Binding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter. Vortioxetine 46-58 solute carrier family 6 member 4 Homo sapiens 72-93 26389667-3 2015 Vortioxetine represents a new class of antidepressant drugs with a multimodal pharmacological profile that in addition to potent inhibition of hSERT include agonistic or antagonistic effects at different serotonin receptors. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 143-148 26389667-4 2015 We used a combination of computational, chemical, and biological methods to decipher the molecular basis for high affinity binding of vortioxetine in hSERT. Vortioxetine 134-146 solute carrier family 6 member 4 Homo sapiens 150-155 26389667-6 2015 Comparative modeling and ligand docking suggest that vortioxetine can adopt several distinct binding modes within the central binding site of hSERT. Vortioxetine 53-65 solute carrier family 6 member 4 Homo sapiens 142-147 26389667-9 2015 The findings provide important new insight about the molecular basis for high affinity recognition of vortioxetine in hSERT, which is essential for future structure-based drug discovery of novel multimodal drugs with fine-tuned selectivity across different transporter and receptor proteins in the human brain. Vortioxetine 102-114 solute carrier family 6 member 4 Homo sapiens 118-123 26174134-2 2015 Vortioxetine, a multimodal antidepressant acting through serotonin (5-HT) transporter (SERT) inhibition, 5-HT3, 5-HT7 and 5-HT1D receptor antagonism, 5-HT1B receptor partial agonism, and 5-HT1A receptor agonism, had fewer incidences of sleep-related adverse events reported in depressed patients. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 87-91 26174134-3 2015 In the accompanying paper a polysomnographic electroencephalography (sleep-EEG) study of vortioxetine and paroxetine in healthy subjects indicated that at low/intermediate levels of SERT occupancy, vortioxetine affected rapid eye movement (REM) sleep differently than paroxetine. Vortioxetine 89-101 solute carrier family 6 member 4 Rattus norvegicus 182-186 26253622-7 2015 The relation between REM suppression parameters and SERT occupancy was significantly different between vortioxetine and paroxetine, despite the same SERT occupancy. Vortioxetine 103-115 solute carrier family 6 member 4 Homo sapiens 52-56 26174134-4 2015 Here we investigated clinically meaningful doses (80-90% SERT occupancy) of vortioxetine and paroxetine on sleep-EEG in rats to further elucidate the serotoninergic receptor mechanisms mediating this difference. Vortioxetine 76-88 solute carrier family 6 member 4 Rattus norvegicus 57-61 26174134-11 2015 The 5-HT3 receptor antagonist ondansetron significantly reduced paroxetine"s acute effects on ROL, while the 5-HT3 receptor agonist SR57227A significantly increased vortioxetine"s acute effect on ROL. Vortioxetine 165-177 5-hydroxytryptamine receptor 3A Rattus norvegicus 109-123 26046533-6 2015 Vortioxetine, but not fluoxetine, increased hippocampal expression of several neuroplasticity-related genes in middle-aged mice (e.g., Nfkb1, Fos, Fmr1, Camk2a, Arc, Shank1, Nlgn2, and Rab3a). Vortioxetine 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 135-140 26489070-5 2015 On the other hand, dosage adjustments may be required when vortioxetine is coadministered with strong CYP2D6 inhibitors or broad-spectrum CYP inducers. Vortioxetine 59-71 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 102-108 26489070-5 2015 On the other hand, dosage adjustments may be required when vortioxetine is coadministered with strong CYP2D6 inhibitors or broad-spectrum CYP inducers. Vortioxetine 59-71 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 102-105 26046533-6 2015 Vortioxetine, but not fluoxetine, increased hippocampal expression of several neuroplasticity-related genes in middle-aged mice (e.g., Nfkb1, Fos, Fmr1, Camk2a, Arc, Shank1, Nlgn2, and Rab3a). Vortioxetine 0-12 FBJ osteosarcoma oncogene Mus musculus 142-145 26046533-6 2015 Vortioxetine, but not fluoxetine, increased hippocampal expression of several neuroplasticity-related genes in middle-aged mice (e.g., Nfkb1, Fos, Fmr1, Camk2a, Arc, Shank1, Nlgn2, and Rab3a). Vortioxetine 0-12 fragile X messenger ribonucleoprotein 1 Mus musculus 147-151 26046533-6 2015 Vortioxetine, but not fluoxetine, increased hippocampal expression of several neuroplasticity-related genes in middle-aged mice (e.g., Nfkb1, Fos, Fmr1, Camk2a, Arc, Shank1, Nlgn2, and Rab3a). Vortioxetine 0-12 calcium/calmodulin-dependent protein kinase II alpha Mus musculus 153-159 26046533-6 2015 Vortioxetine, but not fluoxetine, increased hippocampal expression of several neuroplasticity-related genes in middle-aged mice (e.g., Nfkb1, Fos, Fmr1, Camk2a, Arc, Shank1, Nlgn2, and Rab3a). Vortioxetine 0-12 SH3 and multiple ankyrin repeat domains 1 Mus musculus 166-172 26046533-6 2015 Vortioxetine, but not fluoxetine, increased hippocampal expression of several neuroplasticity-related genes in middle-aged mice (e.g., Nfkb1, Fos, Fmr1, Camk2a, Arc, Shank1, Nlgn2, and Rab3a). Vortioxetine 0-12 neuroligin 2 Mus musculus 174-179 26046533-6 2015 Vortioxetine, but not fluoxetine, increased hippocampal expression of several neuroplasticity-related genes in middle-aged mice (e.g., Nfkb1, Fos, Fmr1, Camk2a, Arc, Shank1, Nlgn2, and Rab3a). Vortioxetine 0-12 RAB3A, member RAS oncogene family Mus musculus 185-190 25524057-2 2015 Vortioxetine is a multimodal acting antidepressant that functions as a 5-HT3 and 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of the 5-HT transporter. Vortioxetine 0-12 solute carrier family 6 member 4 Rattus norvegicus 197-213 26192901-11 2015 Therefore the newest serotonergic antidepressants including vilazodone and vortioxetine have been designed to possess 5-HT(1A) receptor partial agonist properties. Vortioxetine 75-87 5-hydroxytryptamine receptor 1A Homo sapiens 118-135 26035185-1 2015 CONTEXT: Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of action thought to be related to a combination of 2 pharmacologic actions: direct modulation of several receptors and inhibition of the serotonin transporter. Vortioxetine 9-21 solute carrier family 6 member 4 Homo sapiens 211-232 26035186-2 2015 The mechanism of action of vortioxetine is thought to be related to direct modulation of serotonin (5-HT) receptor activity and inhibition of the serotonin transporter. Vortioxetine 27-39 solute carrier family 6 member 4 Homo sapiens 146-167 25665528-1 2015 RATIONALE: Vortioxetine is a novel multimodal antidepressant that is a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist, an inhibitor of the serotonin (5-HT) transporter, and a 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist in vitro. Vortioxetine 11-23 5-hydroxytryptamine receptor 1B Rattus norvegicus 71-77 25665528-1 2015 RATIONALE: Vortioxetine is a novel multimodal antidepressant that is a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist, an inhibitor of the serotonin (5-HT) transporter, and a 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist in vitro. Vortioxetine 11-23 5-hydroxytryptamine receptor 1A Rattus norvegicus 106-112 25665528-1 2015 RATIONALE: Vortioxetine is a novel multimodal antidepressant that is a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist, an inhibitor of the serotonin (5-HT) transporter, and a 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist in vitro. Vortioxetine 11-23 5-hydroxytryptamine receptor 1D Rattus norvegicus 187-193 25665528-2 2015 In vivo studies have shown that vortioxetine enhances levels of 5-HT and desensitizes 5-HT1A autoreceptors. Vortioxetine 32-44 5-hydroxytryptamine receptor 1A Rattus norvegicus 86-92 25665528-3 2015 OBJECTIVES: The aim of the present study was to investigate the effects of acute and long-term administration of vortioxetine on the terminal 5-HT1B receptor and the tonic activation of 5-HT1A receptor in the rat hippocampus. Vortioxetine 113-125 5-hydroxytryptamine receptor 1B Rattus norvegicus 142-148 25665528-6 2015 RESULTS: Vortioxetine enhanced the inhibitory effect of the stimulation of the 5-HT bundle at a high, but not low frequency and reversed the inhibitory effect of the 5-HT1B receptor agonist CP 94253. Vortioxetine 9-21 5-hydroxytryptamine receptor 1B Rattus norvegicus 166-172 25665528-9 2015 Long-term administration of vortioxetine and escitalopram (both at 5 mg/kg/day) induced an increase of tonic activation of the 5-HT1A receptors in CA3 pyramidal neurons, resulting in an increase in 5-HT transmission. Vortioxetine 28-40 5-hydroxytryptamine receptor 1A Rattus norvegicus 127-133 25665528-9 2015 Long-term administration of vortioxetine and escitalopram (both at 5 mg/kg/day) induced an increase of tonic activation of the 5-HT1A receptors in CA3 pyramidal neurons, resulting in an increase in 5-HT transmission. Vortioxetine 28-40 carbonic anhydrase 3 Rattus norvegicus 147-150 25665528-10 2015 In addition, vortioxetine decreased the function of terminal 5-HT1B autoreceptor following its sustained administration. Vortioxetine 13-25 5-hydroxytryptamine receptor 1B Rattus norvegicus 61-67 25665528-11 2015 CONCLUSIONS: Desensitization of 5-HT1B autoreceptor and an increase of tonic activation of 5-HT1A receptors in the hippocampus may contribute to the antidepressant effect of vortioxetine. Vortioxetine 174-186 5-hydroxytryptamine receptor 1B Rattus norvegicus 32-38 25665528-11 2015 CONCLUSIONS: Desensitization of 5-HT1B autoreceptor and an increase of tonic activation of 5-HT1A receptors in the hippocampus may contribute to the antidepressant effect of vortioxetine. Vortioxetine 174-186 5-hydroxytryptamine receptor 1A Rattus norvegicus 91-97 25524057-10 2015 In summary, vortioxetine prevented the effect of stress on hippocampal LTP, increased rapidly hippocampal cell proliferation and enhanced short-term episodic memory, via, at least in part, its 5-HT3 receptor antagonism. Vortioxetine 12-24 5-hydroxytryptamine receptor 3A Rattus norvegicus 193-207 25893002-3 2015 Mechanism of Action : Vortioxetine has 5-HT3, 5-HT7 and 5-HT1D antagonists, 5-HT1B partial agonist and a 5-HT1A agonist and serotonin transporter inhibitor property. Vortioxetine 22-34 5-hydroxytryptamine receptor 1A Homo sapiens 105-111 25418918-4 2014 Vortioxetine is an agonist of 5-HT1A, a partial agonist of 5-HT1B and an antagonist of 5-HT1D, 5-HT3 and 5-HT7 serotoninergic receptors. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 30-36 25016186-1 2015 Vortioxetine, a novel antidepressant for the treatment of major depressive disorder (MDD), is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 174-189 25016186-1 2015 Vortioxetine, a novel antidepressant for the treatment of major depressive disorder (MDD), is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 232-236 25446573-2 2015 Vortioxetine is a multimodal antidepressant that inhibits 5-HT1D, 5-HT3, 5-HT7 receptor activity, 5-HT reuptake, and enhances the activity of 5-HT1A and 5-HT1B receptors. Vortioxetine 0-12 5-hydroxytryptamine (serotonin) receptor 1D Mus musculus 58-64 25446573-4 2015 Incubation of tissue explants from the suprachiasmatic nucleus of PER2::LUC mice with 0.1 muM vortioxetine increased the period length of PER2 bioluminescence. Vortioxetine 94-106 period circadian clock 2 Mus musculus 66-70 25446573-4 2015 Incubation of tissue explants from the suprachiasmatic nucleus of PER2::LUC mice with 0.1 muM vortioxetine increased the period length of PER2 bioluminescence. Vortioxetine 94-106 period circadian clock 2 Mus musculus 138-142 25418918-4 2014 Vortioxetine is an agonist of 5-HT1A, a partial agonist of 5-HT1B and an antagonist of 5-HT1D, 5-HT3 and 5-HT7 serotoninergic receptors. Vortioxetine 0-12 5-hydroxytryptamine receptor 1B Homo sapiens 59-65 25418918-4 2014 Vortioxetine is an agonist of 5-HT1A, a partial agonist of 5-HT1B and an antagonist of 5-HT1D, 5-HT3 and 5-HT7 serotoninergic receptors. Vortioxetine 0-12 5-hydroxytryptamine receptor 1D Homo sapiens 87-93 24846338-2 2014 Vortioxetine is a 5-HT3 , 5-HT7 , and 5-HT1D receptor antagonist, 5-HT1B partial agonist, 5-HT1A agonist, and 5-HT transporter inhibitor. Vortioxetine 0-12 basigin (Ok blood group) Rattus norvegicus 28-31 25717481-8 2014 Vortioxetine is a novel antidepressant with a unique mechanism of action: it acts through the serotonine reuptake inhibition, but works also as 5HT(1A) agonist, as well as partial agonist of the 5HT(1B) receptor and antagonist of the 5HT(1D), 5HT(3) and 5HT(7) receptors. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 144-150 25717481-8 2014 Vortioxetine is a novel antidepressant with a unique mechanism of action: it acts through the serotonine reuptake inhibition, but works also as 5HT(1A) agonist, as well as partial agonist of the 5HT(1B) receptor and antagonist of the 5HT(1D), 5HT(3) and 5HT(7) receptors. Vortioxetine 0-12 5-hydroxytryptamine receptor 1D Homo sapiens 234-240 25122043-1 2014 Vortioxetine, a novel antidepressant with multimodal action, is a serotonin (5-HT)3, 5-HT7 and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist and a 5-HT transporter (SERT) inhibitor. Vortioxetine 0-12 solute carrier family 6 member 4 Rattus norvegicus 190-206 25122043-1 2014 Vortioxetine, a novel antidepressant with multimodal action, is a serotonin (5-HT)3, 5-HT7 and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist and a 5-HT transporter (SERT) inhibitor. Vortioxetine 0-12 solute carrier family 6 member 4 Rattus norvegicus 208-212 25122043-4 2014 Vortioxetine was found to prevent the 5-HT-induced increase in inhibitory post-synaptic potentials recorded from CA1 pyramidal cells, most likely by 5-HT3 receptor antagonism. Vortioxetine 0-12 carbonic anhydrase 1 Rattus norvegicus 113-116 25122043-4 2014 Vortioxetine was found to prevent the 5-HT-induced increase in inhibitory post-synaptic potentials recorded from CA1 pyramidal cells, most likely by 5-HT3 receptor antagonism. Vortioxetine 0-12 5-hydroxytryptamine receptor 3A Rattus norvegicus 149-163 25122043-5 2014 Vortioxetine also enhanced LTP in the CA1 region of the hippocampus. Vortioxetine 0-12 carbonic anhydrase 1 Rattus norvegicus 38-41 24846338-13 2014 CONCLUSIONS AND IMPLICATIONS: Vortioxetine increased wakefulness and increased frontal cortical activity, most likely because of its 5-HT7 and 5-HT3 antagonism and 5-HT1A agonism. Vortioxetine 30-42 basigin (Ok blood group) Rattus norvegicus 135-138 24846338-13 2014 CONCLUSIONS AND IMPLICATIONS: Vortioxetine increased wakefulness and increased frontal cortical activity, most likely because of its 5-HT7 and 5-HT3 antagonism and 5-HT1A agonism. Vortioxetine 30-42 5-hydroxytryptamine receptor 1A Rattus norvegicus 164-170 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 129-135 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 0-12 5-hydroxytryptamine receptor 1B Homo sapiens 137-143 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 0-12 5-hydroxytryptamine receptor 1D Homo sapiens 145-151 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 14-24 5-hydroxytryptamine receptor 1A Homo sapiens 129-135 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 14-24 5-hydroxytryptamine receptor 1B Homo sapiens 137-143 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 14-24 5-hydroxytryptamine receptor 1D Homo sapiens 145-151 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 29-82 5-hydroxytryptamine receptor 1A Homo sapiens 129-135 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 29-82 5-hydroxytryptamine receptor 1B Homo sapiens 137-143 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 29-82 5-hydroxytryptamine receptor 1D Homo sapiens 145-151 24846338-2 2014 Vortioxetine is a 5-HT3 , 5-HT7 , and 5-HT1D receptor antagonist, 5-HT1B partial agonist, 5-HT1A agonist, and 5-HT transporter inhibitor. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Rattus norvegicus 90-96 24570588-1 2014 Vortioxetine is a novel antidepressant with effects on multiple 5-HT receptors and on the serotonin transporter. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 90-111 25075188-1 2014 VORTIOXETINE IS A NEW MULTIMODAL ACTION ANTIDEPRESSANT WITH TWO TYPES OF ACTION: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 81-102 25075188-1 2014 VORTIOXETINE IS A NEW MULTIMODAL ACTION ANTIDEPRESSANT WITH TWO TYPES OF ACTION: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 104-108 24676550-6 2014 DATA SYNTHESIS: Vortioxetine is a novel multimodal antidepressant agent, which inhibits the 5-HT transporter protein, acts as a 5-HT3 antagonist, 5-HT1A receptor agonist, 5-HT7 receptor antagonist, and a partial agonist of the 5-HT1B receptor. Vortioxetine 16-28 5-hydroxytryptamine receptor 1A Homo sapiens 146-161 24311349-4 2014 In vitro studies indicate that vortioxetine is an inhibitor of the 5-HT transporter and is a 5-HT(1D), 5-HT3 and 5-HT7 receptor antagonist, a 5-HT(1A) receptor agonist and a 5-HT(1B) receptor partial agonist. Vortioxetine 31-43 5-hydroxytryptamine receptor 1D Homo sapiens 93-100 24311349-4 2014 In vitro studies indicate that vortioxetine is an inhibitor of the 5-HT transporter and is a 5-HT(1D), 5-HT3 and 5-HT7 receptor antagonist, a 5-HT(1A) receptor agonist and a 5-HT(1B) receptor partial agonist. Vortioxetine 31-43 5-hydroxytryptamine receptor 1A Homo sapiens 142-159 23721744-1 2013 Vortioxetine (Lu AA21004) is an investigational novel antidepressant with multimodal activity that functions as a 5-HT3, 5-HT7 and 5-HT(1D) receptor antagonist, 5-HT(1B) receptor partial agonist, 5-HT(1A) receptor agonist and inhibitor of the 5-HT transporter in vitro. Vortioxetine 0-12 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 243-259 23916504-0 2014 Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Rattus norvegicus 142-148 23916504-0 2014 Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Vortioxetine 0-12 5-hydroxytryptamine receptor 3A Rattus norvegicus 170-184 23916504-8 2014 Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) <=0.1mg/kg (~80% 5-HT3 receptor occupancy; OR) and <=3.0mg/kg (5-HT1A, 5-HT1B, 5-HT3 receptor occupancy: ~15%, 60%, 95%) in SA. Vortioxetine 0-12 5-hydroxytryptamine receptor 3A Rattus norvegicus 124-138 23916504-8 2014 Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) <=0.1mg/kg (~80% 5-HT3 receptor occupancy; OR) and <=3.0mg/kg (5-HT1A, 5-HT1B, 5-HT3 receptor occupancy: ~15%, 60%, 95%) in SA. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Rattus norvegicus 173-179 23916504-8 2014 Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) <=0.1mg/kg (~80% 5-HT3 receptor occupancy; OR) and <=3.0mg/kg (5-HT1A, 5-HT1B, 5-HT3 receptor occupancy: ~15%, 60%, 95%) in SA. Vortioxetine 0-12 5-hydroxytryptamine receptor 1B Rattus norvegicus 181-187 23916504-8 2014 Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) <=0.1mg/kg (~80% 5-HT3 receptor occupancy; OR) and <=3.0mg/kg (5-HT1A, 5-HT1B, 5-HT3 receptor occupancy: ~15%, 60%, 95%) in SA. Vortioxetine 0-12 5-hydroxytryptamine receptor 3A Rattus norvegicus 189-203 23916504-12 2014 vortioxetine administration significantly improved memory performance in OR and occupied 95%, 66%, and 9.5% of 5-HT3, 5-HT1B, and 5-HT1A receptors, respectively. Vortioxetine 0-12 5-hydroxytryptamine receptor 1B Rattus norvegicus 118-124 23916504-12 2014 vortioxetine administration significantly improved memory performance in OR and occupied 95%, 66%, and 9.5% of 5-HT3, 5-HT1B, and 5-HT1A receptors, respectively. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Rattus norvegicus 130-136 23916504-13 2014 Vortioxetine"s effects on SA performance may involve 5-HT1A receptor agonism, but not 5-HT3 receptor antagonism, whereas the effects on OR performance may involve 5-HT3 receptor antagonism and 5-HT1A receptor agonism. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Rattus norvegicus 53-59 24165478-6 2014 DATA SYNTHESIS: Vortioxetine is a multi-modal antidepressant that functions as a human 5-HT3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the serotonin transporter. Vortioxetine 16-28 5-hydroxytryptamine receptor 1A Homo sapiens 158-173 24165478-6 2014 DATA SYNTHESIS: Vortioxetine is a multi-modal antidepressant that functions as a human 5-HT3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the serotonin transporter. Vortioxetine 16-28 solute carrier family 6 member 4 Homo sapiens 204-225 23428337-0 2013 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). Vortioxetine 61-73 solute carrier family 6 member 4 Homo sapiens 0-5 23428337-0 2013 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). Vortioxetine 61-73 5-hydroxytryptamine receptor 1A Homo sapiens 10-17 23721744-13 2013 Vortioxetine effects were observed at low levels of 5-HT transporter occupancy, suggesting an alternative mechanism of action to 5-HT reuptake inhibition. Vortioxetine 0-12 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 52-68 23757185-11 2013 Two new antidepressant drugs, vilazodone (marketed in the USA) and vortioxetine (in development) incorporate partial 5-HT1A-R agonist properties with SERT blockade. Vortioxetine 67-79 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 117-125 23757185-11 2013 Two new antidepressant drugs, vilazodone (marketed in the USA) and vortioxetine (in development) incorporate partial 5-HT1A-R agonist properties with SERT blockade. Vortioxetine 67-79 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 150-154 23380522-2 2013 Vortioxetine (Lu AA21004) in development as a novel multimodal antidepressant is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist and a 5-HT transporter (5-HTT) inhibitor in vitro. Vortioxetine 0-12 solute carrier family 6 member 4 Rattus norvegicus 195-211 23089374-0 2013 The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Vortioxetine 69-81 5-hydroxytryptamine receptor 3A Rattus norvegicus 91-107 23089374-2 2013 Here, we report the effects of the multi-modal antidepressant vortioxetine (Lu AA21004), a 5-HT(3) and 5-HT(7) receptor antagonist, 5-HT(1B) receptor partial agonist, 5-HT(1A) receptor agonist and 5-HT transporter (SERT) inhibitor, on rat 5-HT neurotransmission. Vortioxetine 62-74 solute carrier family 6 member 4 Rattus norvegicus 215-219 23089374-14 2013 This is at least partly due to 5-HT(3) receptor antagonism of vortioxetine in association with its reduced SERT occupancy. Vortioxetine 62-74 5-hydroxytryptamine receptor 3A Rattus norvegicus 31-47 23089374-14 2013 This is at least partly due to 5-HT(3) receptor antagonism of vortioxetine in association with its reduced SERT occupancy. Vortioxetine 62-74 solute carrier family 6 member 4 Rattus norvegicus 107-111